(UroToday.com) It has been long recognized that, in the United States, Black men with prostate cancer have poorer outcomes than White men. This is, at least in part, driven by the fact that Black men are less likely to receive definitive therapy. Further, other health systems factors including sites of care and greater societal factors and historical policies (e.g. “redlining”) have contributed to differential barriers to care among Black men and resulted in a greater proportion of Black men receiving care in resource-deprived settings.